Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Boehringer’s lung drug Spiriva, approved for chronic obstructive pulmonary disease (COPD) and asthma, generated net sales of 2.4 billion euros, down 11.4% compared with last year, which the ...

Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.

As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO.

Currently, Spiriva (tiotropium bromide; Pfizer/Boehringer Ingelheim) is the only LAMA available in the market. Seretide/Advair (fluticasone propionate + salmeterol; GlaxoSmithKline) and Symbicort ...

§ Studies in which clinical cure rate was measured; clinical success rate was analyzed in the majority of the studies. A: Amoxicillin; AC: Amoxicillin and clavulanate; Az: Azithromycin; b ...

Erdosteine is a multimechanism, mucolytic agent that decreases the sputum viscoelastic properties and bacterial adhesion to the cell membrane, endowed with bronchial anti-inflammatory activity and ...

This does not seem to happen with anticholinergic inhalants like Spiriva Respimat (tiotropium bromide) or glycopyrronium bromide, for which there is little risk of tolerance. Nasal decongestant sprays ...

2 GRIAC Research Institute, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands Correspondence to Loes E M Kistemaker, Department of Molecular Pharmacology, ...